<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655353</url>
  </required_header>
  <id_info>
    <org_study_id>ABY-025-MI301</org_study_id>
    <nct_id>NCT03655353</nct_id>
  </id_info>
  <brief_title>A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer</brief_title>
  <acronym>Affibody-3</acronym>
  <official_title>A Multicenter Phase II/III-study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Lindman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affibody</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A large multi- center phase II/III study with 68Ga-ABY-025 PET and biopsies in patients with
      advanced HER2-positive breast cancer, where the primary endpoint of the study is to find out
      the correlation between the HER2 expression measured by 68Ga-ABY-025 PET and standard
      histopathology from relevant tumor biopsies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Investigators will determine HER2 expression by ABY-PET without knowledge of the results from the biopsies (in Phase III part).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HER2- expression by using 68Ga-ABY-025 PET.</measure>
    <time_frame>Approximately 10 days after study entry.</time_frame>
    <description>HER2-expression in tumors measured by 68Ga-ABY-025 PET, centrally analysed and result used for location of biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HER2-expression by analysing biopsy sample.</measure>
    <time_frame>Approximately 21 days after study entry.</time_frame>
    <description>HER2-expression in tumors by histopathology. Location of biopsy site based on HER2 expression seen in ABY-PET.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ABY-PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68Ga-ABY-025 is used as tracer for PET scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ABY-PET</intervention_name>
    <description>Diagnostic PET for HER2 expression</description>
    <arm_group_label>ABY-PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent.

          2. Age ≥18 years.

          3. Histologically or cytologically confirmed HER2-positive or borderline positive (for
             definition see below) adenocarcinoma of the breast.

             HER2-positive defined as:

               1. 3+ by immunohistochemistry [IHC] in &gt;10% of cell areas.

               2. 2+ by IHC in &gt;10% of cell areas and HER2/CEP17 ratio ≥2.0 or HER2 copy number ≥
                  6.0 by in situ hybridization [ISH]).

                  HER2-borderline positive defines as:

               3. 2+ by IHC and HER2/CEP17 ratio &lt;2.0 and/or HER2 copy number 4.0 - 6.0 by in situ
                  hybridization [ISH]) (&quot;equivocal&quot;).

               4. 2+ by IHC and HER2/CEP17 ratio &lt;2.0 and/or HER2 copy number &lt;4.0 by in situ
                  hybridization [ISH]) (&quot;2+ ISH negative&quot;).

               5. Known inhomogeneous HER2-expression in the primary tumor with HER2-positive areas
                  &lt;10% (&quot;inhomogeneous&quot;).

          4. Primary breast cancer planned for neoadjuvant therapy (Stage II-III, T2-4N0-3) or
             metastatic (M1; at least 80 pts).

          5. At least one tumor lesion ≥ 10 mm.

          6. At least one tumor lesion available for biopsy.

          7. Newly diagnosed or confirmed progression and planned for therapy with trastuzumab
             emtansine or anti-HER2 targeted therapy(-ies) concomitant with chemotherapy
             (HER2-positive cohort) or chemotherapy (HER2-negative patients).

          8. WHO performance status ≤ 2.

          9. Predicted survival &gt; 12 weeks.

         10. Negative pregnancy test in women of childbearing potential (premenopausal or &lt;12
             months of amenorrhea post-menopause and who have not undergone surgical
             sterilization). Women of childbearing potential must use highly effective method of
             contraception, i.e combined hormonal contraception, or progestogen-only hormonal
             contraception, or intrauterine device, or intrauterine hormone-releasing system, or
             bilateral tubal occlusion, or vasectomized partner, or sexual abstinence

        Exclusion Criteria:

          1. Histologically or cytologically confirmed HER2-negative breast cancer defined as IHC 0
             or 1+.

          2. Other manifest malignancy.

          3. Serious uncontrolled concomitant disease including congestive heart failure that would
             contraindicate the use of any anti-HER2 therapy.

          4. Inadequate organ function, suggested by the following laboratory results:

               -  Absolute neutrophil count &lt;1,500 cells/mm3

               -  Total bilirubin ≥1.5 x ULN (unless the patient has documented Gilbert's syndrome)

               -  AST (SGOT) or ALT (SGPT) &gt;5.0 × ULN

               -  Serum creatinine clearance &lt;30 ml/min

          5. Patients of childbearing potential and sexually active and not willing to use highly
             effective contraceptive.

          6. Assessed by the Investigator to be unable or unwilling to comply with the requirements
             of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Lindman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lena Franklin, BSc</last_name>
    <phone>+46 18 6111761</phone>
    <email>lena.franklin@akademiska.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tora Sundin</last_name>
    <phone>+46 18 6172428</phone>
    <email>tora.sundin@akademiska.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Section for Clinical Research &amp; Development Unit</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tora Sundin</last_name>
      <email>tora.sundin@akademiska.se</email>
    </contact>
    <contact_backup>
      <last_name>Lena Franklin</last_name>
      <email>lena.franklin@akademiska.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Lindman</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

